Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China
Abstract In recent years, antibody-drug conjugates have become clinically significant in oncology therapeutics. Results from the POLARIX trial revealed that polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab plus cyclophosph...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Portfolio
2025-08-01
|
| Edice: | Scientific Reports |
| Témata: | |
| On-line přístup: | https://doi.org/10.1038/s41598-025-15477-9 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|